Published in Oncol Rep on June 01, 2016
MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma. J Cancer (2017) 0.77
Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget (2017) 0.76
Lymphocyte-specific protein 1 inhibits the growth of hepatocellular carcinoma by suppressing ERK1/2 phosphorylation. FEBS Open Bio (2016) 0.75
Evaluation on the diagnostic and prognostic values of long non-coding RNA BLACAT1 in common types of human cancer. Mol Cancer (2017) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology (2008) 8.24
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol (2011) 8.21
Interaction of plasma membrane fibronectin receptor with talin--a transmembrane linkage. Nature (1986) 8.06
Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res (2009) 7.83
Talin binding to integrin beta tails: a final common step in integrin activation. Science (2003) 7.56
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med (2001) 5.38
Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther (2009) 4.98
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist (2010) 4.68
Regionally restricted developmental defects resulting from targeted disruption of the mouse homeobox gene hox-1.5. Nature (1991) 4.60
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
ENZYMATIC SYNTHESIS OF DEOXYRIBONUCLEOTIDES. IV. ISOLATION AND CHARACTERIZATION OF THIOREDOXIN, THE HYDROGEN DONOR FROM ESCHERICHIA COLI B. J Biol Chem (1964) 4.36
Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol (2014) 4.24
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A (1997) 4.20
MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster. J Biol Chem (2007) 3.71
Hox genes in hematopoiesis and leukemogenesis. Oncogene (2007) 3.55
Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol (2006) 2.97
The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays (2003) 2.91
Replication licensing--defining the proliferative state? Trends Cell Biol (2002) 2.91
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
The thioredoxin system in cancer. Semin Cancer Biol (2006) 2.42
Comparing the MicroRNA spectrum between serum and plasma. PLoS One (2012) 2.34
MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology (2012) 2.29
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2010) 2.28
Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med (1995) 2.24
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol (2011) 2.21
Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res (2009) 2.20
Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol (1998) 2.01
Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell (2000) 2.01
The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology (2010) 1.85
Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood (2003) 1.84
Structure, function and regulation of carboxylesterases. Chem Biol Interact (2006) 1.80
Cancer-related issues of CD147. Cancer Genomics Proteomics (2010) 1.74
Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res (2010) 1.74
The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron (2011) 1.67
Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut (2010) 1.67
Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma. Hepatology (2015) 1.60
miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res (2007) 1.59
The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des (2007) 1.57
Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol (2006) 1.57
Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic Biol Med (2007) 1.56
HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res (2007) 1.48
Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry (2011) 1.48
Dealing with the family: CD147 interactions with cyclophilins. Immunology (2006) 1.46
Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One (2012) 1.43
Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta (2005) 1.42
Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology (1984) 1.41
AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene (2010) 1.40
MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin (2014) 1.40
Identification and characterization of LTBP-2, a novel latent transforming growth factor-beta-binding protein. J Biol Chem (1994) 1.39
Essential role of MCM proteins in premeiotic DNA replication. Mol Biol Cell (2002) 1.38
The function of the chloroplast 2-cysteine peroxiredoxin in peroxide detoxification and its regulation. J Exp Bot (2002) 1.34
MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat (2011) 1.34
Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med (2014) 1.34
miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun (2010) 1.30
NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol (2006) 1.30
High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol (2013) 1.30
MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. Hepatology (2014) 1.30
Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol (2003) 1.29
HOX genes and their role in the development of human cancers. J Mol Med (Berl) (2014) 1.26
The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer (2013) 1.24
Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet (2002) 1.24
Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood. J Thromb Haemost (2010) 1.22
HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells. Hepatology (2011) 1.21
Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res (2002) 1.20
The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal (2013) 1.20
miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem (2009) 1.19
Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection. Lung Cancer (2008) 1.18
Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res (2001) 1.17
Expression of Ku70 and Ku80 mediated by NF-kappa B and cyclooxygenase-2 is related to proliferation of human gastric cancer cells. J Biol Chem (2002) 1.15
New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med (2007) 1.15
Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J Cell Biochem (2008) 1.14
Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. Int J Mol Med (2009) 1.13
The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther (2004) 1.12
Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J Proteome Res (2008) 1.12
Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. Gene (2013) 1.11
Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid Redox Signal (2011) 1.11
Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med (2013) 1.11
Latent transforming growth factor-beta-binding protein 2 is an adhesion protein for melanoma cells. J Biol Chem (2003) 1.10
Transferrin recycling in reticulocytes: pH and iron are important determinants of ligand binding and processing. Biochem Biophys Res Commun (1983) 1.10
MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg (2011) 1.10
Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep (2009) 1.08
Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res (2011) 1.08
Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch (2001) 1.07
miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun (2010) 1.06
ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics (2010) 1.03
Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics (1998) 1.02
Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett (2010) 1.02
Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int (2014) 1.01
Extracellular membrane-proximal domain of HAb18G/CD147 binds to metal ion-dependent adhesion site (MIDAS) motif of integrin β1 to modulate malignant properties of hepatoma cells. J Biol Chem (2011) 1.01
Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Exp Mol Med (2007) 0.99
Axl as a mediator of cellular growth and survival. Oncotarget (2014) 0.99